+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Specific, Estrogen-Sensitive Alterations in Anterior Pituitary Cytoplasmic and Nuclear Estrogen Receptors Actuated by LHRH



      S. Karger AG

      Estrogen receptor, LHRH, TRH, Pituitary, LHRH agonist

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          We have previously demonstrated that LHRH is capable of eliciting a dramatic and direct elevation of anterior pituitary levels of nuclear estrogen receptors (E2R) [18, 24]. This action was manifest under both in vitro and in vivo conditions, and could not be attributed to an amplification of the rate or extent of cytosol E2R binding, activation or transloca-tion. In view of the implications of these observations in terms of estrogen-LHRH interplay in regulation of gonadotropin secretion, we have further explored the nature, specificity and estrogen dependency of the LHRH effect. TRH, a long-acting agonist, (D-Ala<sup>6</sup>, des-Gly<sup>10</sup>)LHRH-N-ethylamide (LHRH-A), and an antagonist, N-Ac-D-p-Cl-Phe<sup>12</sup>, D-Trp<sup>3</sup>, D-Phe<sup>6</sup>, D-Ala<sup>10</sup>-LHRH (LHRH-ANT), were compared with LHRH for their ability to alter compartmental E2R concentrations following incubation in vitro. Either intact dispersed anterior pituitary cells or isolated cytosol and nuclei from pituitary homogenates were used as receptor source. LHRH-A and LHRH both caused a 40–60% decrease in the cytoplasmic E2R binding capacity of intact cells following incubation of 30 min at 37 °C; the magnitude of the inhibition was dose independent over a peptide range of 0.1–1000 pmol/pituitary. In contrast, TRH caused a dose-related decrease in cytosol E2R binding. When nuclear E2R levels were assessed, significant dose dependent increases were observed with both LHRH and LHRH-A treatment. The effective dose of LHRH-A was approximately an order of magnitude lower than that of LHRH. TRH, on the other hand, over a wide concentration range (0.3–3,000 pmol/pituitary), had no significant effect on specific nuclear estrogen binding. In isolated nuclei, as in the intact cell studies, LHRH and LHRH-A were stimulatory, while TRH effected no alteration of E2R binding levels. The LHRH effect could be totally blocked by LHRH-ANT. In isolated cytosol, TRH did not affect E2R binding, whereas LHRH and LHRH-A were both mildly stimulatory. The effectiveness of LHRH in enhancing nuclear E2R binding correlated directly with the endogenous estrogen titers of the animals. In tissue from ovariectomized animals primed with 0.1 μg estradiol/day, LHRH was 4 times more potent as a stimulator of nuclear E2R than in tissue from nonprimed castrate animals. If the priming dose was increased to 1.0 μg/day, a further significant increase in sensitivity of nuclear E2R to LHRH was observed over the 0.1 μg priming dose level. The results of these studies attest to the releasing hormone specificity of changes in anterior pituitary E2R levels, and to the involvement of estrogen-LHRH sensitization in this process, analogous to the well-documented estrogen-LHRH interplay in regulation of LHRH release.

          Related collections

          Author and article information

          S. Karger AG
          27 March 2008
          : 37
          : 2
          : 98-105
          Department of Endocrinology, Medical College of Georgia, Augusta, Ga, USA
          123526 Neuroendocrinology 1983;37:98–105
          © 1983 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8
          Original Paper


          Comment on this article